Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Dyne Therapeutics, Inc. incurred term loan of $50.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.
- Instrument
- term loan
- Principal
- $50.0 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45%
- Maturity
- July 1, 2030
- Event
- incurrence
Exact text from the filing
On December 8, 2025 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the First Amendment (the “First Amendment”) to Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions party thereto as lenders (collectively, the “Lenders”). The First Amendment amended certain of the tranche sizes and funding milestone requirements under the Loan and Security Agreement, dated as of June 27, 2025 (the “Initial Loan Agreement” and, such Initial Loan Agreement as amended by the First Amendment, the “Loan Agreement”), by and among the Company, Hercules and the Lenders and permitted the Company to borrow, as of the Amendment Closing Date, a second term loan tranche in an aggregate principal amount of $50.0 million. Following entry into the First Amendment and the borrowing of the second term loan tranche, the Company has two additional term
View on SEC.gov